Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Altered pathways as a biomarker for disease outcomes in CLL

Carsten Niemann • 9 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia

Carsten Niemann, MD, PhD, of Copenhagen University Hospital, Copenhagen, Denmark, describes how the number of signaling pathways altered by driver mutations in chronic lymphocytic leukemia (CLL) impacts disease outcome. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Paper: https://clincancerres.aacrjournals.org/content/26/6/1507

More from Carsten Niemann

Richter’s transformation: biology & ongoing trials in the field
Carsten Niemann et al. • 25 Mar 2024
3:20
Explainable machine learning to identify CLL-driven changes on the gut microbiome
Carsten Niemann • 6 Oct 2023
3:27
The implementation of a data-driven CLL-TIM algorithm into an EPIC-based electronic health record
Carsten Niemann • 6 Oct 2023
2:25
Monitoring infection risk in patients with CLL & insights into the PreVent-ACaLL trial
Carsten Niemann • 6 Oct 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals